Maxim Group Analysts Give Galmed Pharmaceuticals Ltd. (GLMD) a $14.00 Price Target

Maxim Group set a $14.00 price objective on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in a research note issued to investors on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

GLMD has been the topic of several other reports. ValuEngine upgraded shares of Galmed Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, June 17th. HC Wainwright increased their price target on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.00 price objective on the stock in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $14.75.

Galmed Pharmaceuticals (GLMD) opened at 9.32 on Thursday. Galmed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $9.48. The stock’s 50 day moving average is $8.28 and its 200-day moving average is $6.44. The stock’s market capitalization is $113.88 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million. Equities research analysts anticipate that Galmed Pharmaceuticals will post ($0.94) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Maxim Group Analysts Give Galmed Pharmaceuticals Ltd. (GLMD) a $14.00 Price Target” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/08/maxim-group-analysts-give-galmed-pharmaceuticals-ltd-glmd-a-14-00-price-target.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:G

GLMD has been the topic of several other reports. ValuEngine upgraded shares of Galmed Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, June 17th. HC Wainwright increased their price target on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a hold rating to a buy rating and set a $8.00 price objective on the stock in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $14.75.

Galmed Pharmaceuticals (GLMD) opened at 9.32 on Thursday. Galmed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $9.48. The stock’s 50 day moving average is $8.28 and its 200-day moving average is $6.44. The stock’s market capitalization is $113.88 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million. Equities research analysts anticipate that Galmed Pharmaceuticals will post ($0.94) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Maxim Group Analysts Give Galmed Pharmaceuticals Ltd. (GLMD) a $14.00 Price Target” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/08/maxim-group-analysts-give-galmed-pharmaceuticals-ltd-glmd-a-14-00-price-target.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned 0.15% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 8.32% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply